Chromosome instability (CIN) is the most common form of genome instability and is a hallmark of cancer. CIN invariably leads to aneuploidy, a state of karyotype imbalance. Here, we show that aneuploidy can also trigger CIN. We found that aneuploid cells experience DNA replication stress in their first S-phase and precipitate in a state of continuous CIN. This generates a repertoire of genetically diverse cells with structural chromosomal abnormalities that can either continue proliferating or stop dividing. Cycling aneuploid cells display lower karyotype complexity compared to the arrested ones and increased expression of DNA repair signatures. Interestingly, the same signatures are upregulated in highly-proliferative cancer cells, which might enable them to proliferate despite the disadvantage conferred by aneuploidy-induced CIN. Altogether, our study reveals the short-term origins of CIN following aneuploidy and indicates the aneuploid state of cancer cells as a point mutation-independent source of genome instability, providing an explanation for aneuploidy occurrence in tumors.
Mitotic errors lead to aneuploidy, a condition of karyotype imbalance, frequently found in cancer cells. Alterations in chromosome copy number induce a wide variety of cellular stresses, including genome instability. Here, we show that cancer cells might exploit aneuploidy-induced genome instability to survive under conditions of selective pressure, such as chemotherapy. Resistance to chemotherapeutic drugs was dictated by the acquisition of recurrent karyotypes, indicating that gene dosage, together with mutational burden, might play a role in driving chemoresistance. Thus, our study establishes a causal link between aneuploidy-driven genome instability and chemoresistance and might explain why some chemotherapies fail to succeed.
Genome instability is a hallmark of cancer. The most common form of genome instability is chromosomal instability (CIN), a condition in which cells mis-segregate their chromosomes during cell division. CIN leads to aneuploidy, a state of karyotype imbalance, often found in tumors. Although the causal relationship between CIN and aneuploidy is well established, evidence is limited for a direct involvement of aneuploidy in promoting CIN. Here, we show that aneuploid cells experience DNA replication stress in their first S-phase and precipitate in a state of continuous CIN, eventually accumulating complex karyotypes. Mechanistically, we find that aneuploid cells fire dormant replication origins through a Dbf4-dependent kinase (DDK)-driven mechanism and complete replication of genomic loci through mitotic DNA synthesis (MiDAS). By following the fate of aneuploid cells, we also show that, when they divide, DNA damage can be distributed asymmetrically between daughter cells, and this may partially explain why some aneuploid cells are able to continue proliferating and others stop dividing. We further found that cycling aneuploid cells display lower karyotype complexity compared to arrested ones and increased expression of gene signatures associated to DNA repair. Interestingly, by stratifying aneuploid human cancer cells by their doubling times, we found the same DNA repair signatures to be upregulated in highly-proliferative cancer cells, which might enable them to keep proliferating despite the disadvantage conferred by aneuploidy-induced genome instability. In summary, our study reveals the origins of genome instability following induction of aneuploidy and indicates the aneuploid state of cancer cells as a point mutation-independent source of genome instability, providing an explanation for the high occurrence of aneuploidy in tumors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.